Recent trends in the management of advanced prostate cancer [version 1; peer review: 3 approved]

Chad Ritch, Michael Cookson

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Advanced prostate cancer includes a wide spectrum of disease ranging from hormone naïve or hormone sensitive to castration resistant, both containing populations of men who have demonstrable metastatic and non-metastatic states. The mainstay of treatment for metastatic hormone-sensitive prostate cancer is androgen deprivation therapy (ADT). However, recent level 1 evidence demonstrates that the addition of chemotherapy or abiraterone acetate to ADT results in significant survival advantage as compared with ADT alone. Furthermore, in non-metastatic castration-resistant prostate cancer (M0 CRPC), two second-generation anti-androgens, apalutamide and enzalutamide, when used in combination with ADT, have demonstrated a significant benefit in metastasis-free survival. Here, we review the most recent studies leading to these significant changes in the treatment of advanced prostate cancer.

Original languageEnglish (US)
Article number1513
StatePublished - 2018


  • Castration resistant prostate cancer
  • Chemohormonal therapy
  • Hormone sensitive metastatic prostate cancer
  • Prostate cancer

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Recent trends in the management of advanced prostate cancer [version 1; peer review: 3 approved]'. Together they form a unique fingerprint.

Cite this